Clinically, CBL mutations were associated with a more proliferative phenotype evidenced by increased bone marrow blasts, leukocytosis and splenomegaly, similar to other RAS pathway mutations such as KRAS, NRAS and PTPN11. Here, KRAS is linked to Splenomegaly.